Ayala Pharmaceuticals Inc (ADXS)

[jaxstraw]

KANSAS CITY, Kan., July 2, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (NASDAQ: ADXS) for the treatment of canine osteosarcoma and other cancers. While the USDA has no specific obligation to respond within a prescribed timeframe, Aratana anticipates that responses from the USDA to the filing will occur over the next 12 to 18 months.